Mark did graduate work in molecular immunology at Oxford University Institute of Molecular Medicine and Southampton University Cancer Sciences. In his postdoctoral work at MIT he developed tools in chemical biology, advanced microscopy and nanotechnology to understand receptor trafficking. He was Professor of Protein Nanotechnology at Oxford University, moving to Cambridge University to take up the Sheild Chair in the Department of Pharmacology in 2022. In 2017 he was awarded the Royal Society of Chemistry Norman Heatley Prize for chemical biology and helped to found SpyBiotech, taking the group’s vaccine approach into clinical trials.
https://www.phar.cam.ac.uk/research/Howarth/research
Vaccine platforms, VLPs, protein superglue, zoonoses, outbreak pathogens